Search Results
Your search for early matches 10129 pages
Showing 5051 - 5100David J. Sugarbaker, MD, Pioneer in Thoracic Surgery, Mesothelioma, Dies at 65
DAVID J. SUGARBAKER, MD, was an internationally recognized thoracic surgeon who specialized in the treatment of mesothelioma and complex thoracic cancers. To be recognized as first in a medical finding or procedure is a rare honor; Dr. Sugarbaker received that honor twice, being the first to...
Omission of Axillary Dissection in Early Breast Cancer
In a study reported in JAMA Oncology, Monica Morrow, MD, of the Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, and colleagues found that surgeon acceptance of more limited surgery in early breast cancer was more likely among high-volume surgeons and those preferring ...
TGFβ Polymorphism and Radiation-Induced Fibrosis in Breast Cancer
In an analysis reported in JAMA Oncology, Benjamin D. Smith, MD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues found that a single nucleotide polymorphism (C−509T) in the transforming growth factor β1 (TGFβ1) gene was associated with...
Neoadjuvant Therapy, Changes in Body Composition, and Resectability in Pancreatic Cancer
In a retrospective cohort study reported in JAMA Surgery, Carlos Fernández-del Castillo, MD, of the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, and colleagues found that neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma was associated with...
Second Allogeneic HCT vs Donor Lymphocyte Infusion in Relapsed Acute Myeloid Leukemia
In a retrospective registry study reported in JAMA Oncology, Mohamad Mohty, MD, PhD, of Hôpital Saint Antoine, Université Pierre et Marie Curie, and colleagues found no overall survival difference with second allogeneic hematopoietic cell transplantation (HCT) vs donor lymphocyte infusion (DLI) in ...
Expect Questions About Genetic Testing for Breast Cancer
A STUDY finding that pathogenic variants in 5 genes are associated with a high risk of triple-negative breast cancer and a 20% lifetime risk for overall breast cancer1 may increase interest in genetic testing. “This is the first study to establish which genes are associated with high lifetime risks ...
Mutations in Five Genes Linked to Higher Lifetime Risks for Aggressive Breast Cancer
USING MULTIGENE hereditary cancer panels to test for mutations in five genes can identify women at high risk for triple-negative breast cancer who may then benefit from more frequent screening, risk management, and potentially targeted therapies as well. A study that looked at multigene panel...
Pertuzumab in Adjuvant Treatment of HER2-Positive Breast Cancer
AT THE END OF 2017, pertuzumab (Perjeta) was granted regular approval for use in combination with trastuzumab (Herceptin) and chemotherapy as adjuvant treatment of patients with HER2- positive early breast cancer at high risk of recurrence.1,2 Supporting Efficacy Data APPROVAL WAS BASED on...
Lasker Foundation Announces 2018 Awards in Basic and Clinical Medical Research
THE ALBERT and Mary Lasker Foundation has announced the winners of its 2018 Lasker Awards: C. David Allis, PhD, of Rockefeller University, and Michael Grunstein, PhD, of the University of California, Los Angeles, will receive the Albert Lasker Basic Medical Research Award; John B. Glen, BVMS, PhD,...
Department of Defense Grant to Prostate Cancer Researchers
THE U.S. DEPARTMENT of Defense Prostate Cancer Research Program has awarded a grant of more than $900,000 to Weill Cornell Medicine, in collaboration with Columbia University Irving Medical Center and NewYork-Presbyterian to conduct prostate cancer clinical trials. The Prostate Cancer Research...
Abiraterone Acetate Plus Prednisone in High-Risk Metastatic Castration-Sensitive Prostate Cancer
IN EARLY 2018, abiraterone acetate tablets (Yonsa, Zytiga) in combination with prednisone was approved for the treatment of metastatic high-risk castration-sensitive prostate cancer.1,2 Supporting Efficacy Data APPROVAL WAS BASED on findings from the phase III LATITUDE trial, in which 1,199...
Understanding the Different Perspectives on Cost and Value in Cancer Care
The estimated cost of cancer care in the United States was $125 billion in 2010 and is expected to rise to $175 billion by 2020.1 In an effort to reign in spiraling costs and deliver better care, the term “value” has become part of the new oncology lexicon, as providers, patients, and payers seek...
Prostate Cancer Foundation Announces 2018 Young Investigator Award Recipients
THE PROSTATE CANCER FOUNDATION (PCF) recently announced the 29 recipients of the 2018 Young Investigator Awards. Sponsored by the PCF, the Young Investigator Awards program provides both financial support and a comprehensive career development program to early career scientists to conduct critical...
ASCO Journals Editorial Fellowship
Scientific journals are a cornerstone of medical knowledge, delivering information about the latest research discoveries to the medical professionals who will put them into practice. Once a manuscript is submitted, a journal editor guides it through peer review, extensive editing, and publication....
ASCO and Friends of Cancer Research Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
On August 8, ASCO and Friends of Cancer Research (Friends) submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration...
Meet Your ASCO President-Elect, Dr. Howard A. ‘Skip’ Burris
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time ASCO member and volunteer, began his role as ASCO President-Elect in June 2018. An ASCO member for nearly 30 years, Dr. Burris’ service to the Society is extensive. His volunteer roles include member of the ASCO Board of Directors and...
Wally Curran, MD, FACR, FASCO, Reflects on a Career in Academic Oncology
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. Find him on Twitter @jamecancerdoc. For this installment of the Living a Full Life series, guest editor, Jame Abraham, MD,...
Origins and Genetics Associated With Mixed-Phenotype Acute Leukemia
Investigators have unraveled the origins and identified mutations associated with mixed-phenotype acute leukemia. The study, published by Alexander et al in Nature, potentially lays the foundation for more effective treatment of patients with this high-risk cancer. Mixed-phenotype acute...
Actively Recruiting Clinical Trials Focused on Gynecologic Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on gynecologic cancers—cervical, vaginal, uterine, ovarian, and vulvar cancers. These trials are studying chemoradiotherapy combination treatments, cancer vaccines, intraperitoneal ...
CAR T-Cell Therapy for CLL
A pair of new studies from researchers at the Abramson Cancer Center of the University of Pennsylvania are shedding light on why patients with advanced chronic lymphocytic leukemia (CLL) respond or do not respond to chimeric antigen receptor (CAR) T-cell therapy. Although CAR T-cell therapy is...
ASH Honors Ross L. Levine, MD, With 2018 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2018 William Dameshek Prize to Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, for his discoveries in the field of leukemia and myeloproliferative neoplasms during the 2018 ASH Annual Meeting ...
Treatment of Triple-Negative Breast Cancer With BRCA1/2 Mutations: More to Learn From Ongoing Trials
The treatment of triple-negative breast cancer remains a clinical challenge with no single validated target, though numerous pathways are druggable and are being investigated. In the subset of BRCA-mutated triple-negative breast cancer, the approval of the first poly (ADP-ribose) polymerase (PARP)...
Risk of Second HPV-Associated Cancer Among Survivors of HPV-Associated Cancers
A retrospective study led by researchers at Baylor College of Medicine and The University of Texas Health Science Center at Houston (UTHealth) School of Public Health found that survivors of human papillomavirus (HPV)-associated cancers have a high incidence of developing second ...
Uncommon Lethal Complications of Immune Checkpoint Inhibitors
In a systematic review and meta-analysis reported in JAMA Oncology, Wang et al identified frequency and types of fatal toxic effects in patients receiving immune checkpoint inhibitor therapy. Study Details The study involved analysis of fatal immune checkpoint inhibitor–associated toxic...
Neonatal Dysregulated Immune Function and Pediatric B-Cell Precursor ALL
A high incidence of clinically diagnosed infections in the first year of life among children who later developed acute lymphoblastic leukemia (ALL) has led researchers to propose that children with ALL are born with a dysregulated immune function, resulting in a more vigorous reaction to infections ...
Presurgical CT Imaging of CD117-Positive Kidney Tumors
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine—before surgery—whether the tumor is benign or malignant. Their findings...
10-Year Follow-up of Axillary Dissection vs No Dissection in Breast Cancer With Sentinel Node Micrometastases
In the 10-year follow-up of the phase III International Breast Cancer Study Group (IBCSG) 23-01 trial reported in The Lancet Oncology, Galimberti et al found no significant difference in disease-free survival with axillary dissection vs no axillary dissection in patients with breast cancer and...
Lasker Foundation Announces 2018 Lasker Awards for Basic and Clinical Medical Research and Special Achievement
The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis, PhD, of Rockefeller University and Michael Grunstein, PhD, of the University of California, Los Angeles, will receive the Albert Lasker Basic Medical Research...
Somatic Mutations in ER-Positive Breast Cancer and Prognosis
Recent research and genomic studies have revealed a number of genes that accumulate somatic mutations and alterations in estrogen receptor (ER)–positive breast cancer. However, while a few alterations are quite common and relatively well-understood, many genes are mutated in less than 5% of...
Small Study Shows Chemotherapy May Lead to Early Menopause in Young Women With Lung Cancer
A new study suggests chemotherapy may cause acute amenorrhea, leading to early menopause in women with lung cancer. The study is the first to comment on amenorrhea rates in women younger than 50, concluding that women with lung cancer who desire future fertility should be educated about risks and...
Applying for a Conquer Cancer Research Grant: Tips From Past YIA and CDA Recipients
Research grants are vital to the success of academic research and researchers apply for these grants at all stages of their career. This makes writing stand-out grant applications an incredibly valuable skill for clinical investigators—and an intimidating task for first-time grant applicants....
Lung Cancer Expert Leora Horn, MD, Recalls Her Journey to a Career in Oncology and a Home in Nashville
The tumultuous history of modern South Africa has numerous stories that lie beneath the surface of the sociopolitical headlines, such as the story of lung cancer expert Leora Horn, MD. “I was born and reared in Johannesburg, South Africa, a second-generation African family. In 1987, because of the...
Expanding the Use of Provider Orders for Life-Sustaining Treatment for Patients With Advanced Cancer
Patients with advanced cancer often get more aggressive treatment than they want because too few oncologists elicit their end-of-life treatment preferences.1,2 In response to this problem, leading associations, including ASCO3,4 and the Institute of Medicine,5 have called for more advance care...
Brian C. Capell, MD, PhD, Receives Award for Skin Cancer Research
BRIAN C. CAPELL, MD, PhD, Assistant Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, has received a Damon Runyon Clinical Investigator Award. He plans to use the $450,000 research grant to study epigenetic targets in the skin to develop more effective...
Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?
USING THE National Cancer Database, Bhatt et al1 recently reported that of the 61,775 adults with acute myeloid leukemia (AML), those who received chemotherapy from 2003 to 2011 lived longer than those who, in those same years, did not; the study is reviewed in this issue of The ASCO Post....
Suboptimal Use of Initial Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia
IN A STUDY of National Cancer Database data reported in Blood Advances, Vijaya Raj Bhatt, MD, of the University of Nebraska Medical Center, and colleagues found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that...
Relapsed or Refractory Hodgkin Lymphoma: Optimizing Salvage Therapy
As novel therapies come on board for treating relapsed or refractory Hodgkin lymphoma, the field is advancing toward more personalized therapy. The goal, even in the advanced-disease setting, is to increase the chances of complete response and negative positron-emission tomography (PET), while...
Over 130 Buildings and Landmarks in the United States and Canada to Be Illuminated in Support of Stand Up To Cancer's 6th Live Telecast
More than 130 iconic buildings and landmarks across the United States and Canada will be illuminated in a show of support for the 6th biennial Stand Up To Cancer (SU2C) “roadblock” telecast airing in both countries on Friday, September 7 (8:00–9:00 PM ...
PDL1 Amplification in Solid Tumors
In a study reported in JAMA Oncology, Aaron M. Goodman, MD, of the University of California, San Diego Moores Center for Personalized Cancer Therapy, and colleagues found amplification of PDL1 genes in 0.7% of solid tumors, including more than 100 tumor types. Response to checkpoint inhibition was ...
Treating Nonmetastatic Castration-Resistant Prostate Cancer: Implications of the PROSPER Trial
A MAN in his early 70s sits in our office. His general health is good, and he is feeling well. Yet he is deeply worried. Four years ago, when his prostate-specific antigen (PSA) level rapidly increased after radical prostatectomy and subsequent radiation therapy, he was started on...
NCCN and CAOH Develop Guidelines to Improve Cancer Care in the Caribbean
The National Comprehensive Cancer Network® (NCCN®) is embarking on a new collaboration with the Caribbean Association for Oncology & Hematology (CAOH) to develop a library of NCCN Harmonized Guidelines™ for the Caribbean. The archipelago that extends from the Bahamas in the north to Trinidad...
Genetic Forecasting May Predict Response to Cetuximab in Colorectal Cancer
Blood tests could predict how long it takes until colorectal cancer becomes resistant to treatment based on the same principle used in forecasting the weather, a new study by Khan et al in Cancer Discovery has found. The liquid biopsies could also predict patients that are unlikely to initially...
Rates of Inherited Breast Cancer in Nigerian Women
In a study reported in the Journal of Clinical Oncology, Zheng et al found a high frequency of inherited breast cancer among Nigerian women, with presence of deleterious mutations posing very high risk of disease. As noted by the investigators, “…Among Nigerian women, breast cancer is ...
Protein-Metabolite Panel for Detection of Early-Stage Pancreatic Cancer
In a study reported in the Journal of the National Cancer Institute, Fahrmann et al developed and validated a plasma-derived metabolite panel that distinguished early-stage pancreatic ductal adenocarcinoma (PDAC) with high accuracy. Accuracy was further improved with the addition of a previously...
First Large-Scale Survey of APPs in Oncology Shows Growing Role for Nurse Practitioners and Physician Assistants
Advanced practice providers (APPs) have increasingly become integral members of the oncology care delivery team, according to the first large-scale study of nurse practitioners (NPs) and physician assistants (PAs) in oncology. The study was conducted collaboratively by ASCO, the American Academy of ...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of subsolid nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
Bringing Together Industry, Academia, and Nonprofits to Advance Breast Cancer Research
In 2016, the Breast Cancer Research Foundation (BCRF) launched the Drug Research Collaborative, a program the foundation developed to bridge the gap between academic investigators and their access to therapies under investigation and to encourage greater academia-driven research in breast cancer....
Study Examines Link Between Squamous Cell Carcinoma and Recessive Dystrophic Epidermolysis Bullosa
Many patients with the rare skin disease recessive dystrophic epidermolysis bullosa (RDEB)—commonly called butterfly syndrome—also develop squamous cell carcinoma early in life. Now an international team of scientists led by researchers at the Sidney Kimmel Cancer...
Sequential Liquid Biopsy Sampling May Be a Predictive Tool for Early Disease Progression in Patients With Colorectal Cancer
According to the American Cancer Society, excluding skin cancers, colorectal cancer is the third most common cancer among men and women in the United States, with over 97,000 new cases expected this year, and is the third leading cause of cancer-related death, with over 50,000 deaths predicted in...
Tumor Mutation Burden and Prognosis in Resected NSCLC
In a study reported in the Journal of Clinical Oncology, Devarakonda et al found that high nonsynonymous tumor mutation burden was associated with improved outcomes in patients undergoing resection for non–small cell lung cancer (NSCLC). Study Details The study (Lung Adjuvant Cisplatin...
